

Journal of Visualized Experiments

Masarimycin, a small molecule inhibitor of Gram-positive bacterial growth.

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE63191R2
Full Title:	Masarimycin, a small molecule inhibitor of Gram-positive bacterial growth.
Corresponding Author:	Christopher Reid UNITED STATES
Corresponding Author's Institution:	
Corresponding Author E-Mail:	creid@bryant.edu
Order of Authors:	Mika Gallati Bryant Point Christopher Reid
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Biochemistry
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Smithfield, Rhode Island USA
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the Video Release
Please provide any comments to the journal here.	

TITLE:

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth.

AUTHORS AND AFFILIATIONS:

Mika Gallati¹, Bryant Point¹, Christopher W. Reid^{1,2}

¹Department of Science and Technology, Bryant University

²Center for Health and Behavioral Sciences, Bryant University

Corresponding Author:

Christopher W. Reid (creid@bryant.edu)

Email addresses of co-authors:

Mika Gallati (mikagallati@gmail.com)

Bryant Point (bpoint1989@gmail.com)

Christopher W. Reid (creid@bryant.edu)

KEYWORDS:

Peptidoglycan, metabolism, autolysin, chemical biology, inhibitor, cell wall

SUMMARY:

A detailed protocol is presented for preparing the bacteriostatic diamide masarimycin, a small molecule probe that inhibits the growth of *Bacillus subtilis* and *Streptococcus pneumoniae* by targeting cell wall degradation. Its application as a chemical probe is demonstrated in synergy/antagonism assays and morphological studies with *B. subtilis* and *S. pneumoniae*.

ABSTRACT:

Peptidoglycan (PG) in the cell wall of bacteria is a unique macromolecular structure that confers shape, and protection from the surrounding environment. Central to understanding cell growth and division is the knowledge of how PG degradation influences biosynthesis and cell wall assembly. Recently, the metabolic labeling of PG through the introduction of modified sugars or amino acids has been reported. While chemical interrogation of biosynthetic steps with small molecule inhibitors is possible, chemical biology tools to study PG degradation by autolysins are underdeveloped. Bacterial autolysins are a broad class of enzymes that are involved in the tightly coordinated degradation of PG. Here, a detailed protocol is presented for preparing a small molecule probe, masarimycin, which is an inhibitor of N-acetylglucosaminidase LytG in *Bacillus subtilis*, and cell wall metabolism in *Streptococcus pneumoniae*. Preparation of the inhibitor via microwave-assisted and classical organic synthesis is provided. Its applicability as a tool to study Gram-positive physiology in biological assays is presented.

INTRODUCTION:

Peptidoglycan (PG) is a mesh-like polymer that delineates cell shape and structure in both Gram-positive and Gram-negative bacteria^{1,2}. This heteropolymer is a matrix of amino sugars cross-linked by short peptides³⁻⁶ with a backbone composed of β -(1,4)-linked alternating N-

acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues (**Figure 1**)¹. Attached to the C-3 lactyl moiety of MurNAc is the stem peptide. The metabolism of PG involves a tightly coordinated system of biosynthetic and degradative enzymes to incorporate new material into the cell wall^{7,8}. Degradation of PG is carried out by enzymes collectively referred to as autolysins⁹ and further classified based on the specificity of the bond cleaved. Autolysins participate in many cellular processes including cell growth, cell division, motility, PG maturation, chemotaxis, protein secretion, genetic competence, differentiation, and pathogenicity^{10,11}. Unraveling the specific biological functions of individual autolysins can be daunting, due in part to functional redundancy. However, recent biophysical^{8,12,13} and computational studies¹² have provided new insight into their roles in PG metabolism. In addition, recent reports have provided further insight into the synthesis¹⁴ and membrane-mediated^{15–17} steps in PG metabolism. A thorough understanding of the relationship between degradative and synthetic pathways of PG metabolism could give rise to previously untapped antibiotic targets.

While there have been significant advances in methodology to study glycobiology in eukaryotes, bacterial glycobiology and, in particular, PG metabolism has not advanced at a similar rate. Current chemical approaches to study PG metabolism include fluorescently labeled antibiotics¹⁸, fluorescent probes^{19,20}, and metabolic labeling^{21–24}. These new approaches are providing new ways to interrogate bacterial cell wall metabolism. While some of these strategies are capable of labeling PG *in vivo*, they can be species-specific¹⁹, or only work in strains lacking a particular autolysin²⁵. Many PG labeling strategies are intended for use with isolated cell walls²⁶ or with *in vitro* reconstituted PG biosynthesis pathways^{20,27,28}. The use of fluorescently labeled antibiotics is currently limited to biosynthetic steps and transpeptidation¹⁸.

The current knowledge of bacterial autolysins and their role in cell wall metabolism comes from genetic and *in vitro* biochemical analysis^{11,29–32}. While these approaches have provided a wealth of information on this important class of enzymes, deciphering their biological role can be challenging. For instance, due to functional redundancy³³, deletion of an autolysin in most cases does not result in halting bacterial growth. This is despite their implied role in cell growth and division^{7,12}. Another complication is that genetic deletion of bacterial autolysins can give rise to meta-phenotypes³⁴. Meta-phenotypes arise from the complex interplay between the pathway affected by the genetic deletion and other interconnected pathways. For instance, a meta-phenotype can arise *via* a direct effect such as the lack of an enzyme, or an indirect effect such as a disruption of regulators.

Currently, there are only a few inhibitors of glycosidase autolysins such as N-acetylglucosaminidases (GlcNAcase) and N-acetylmuramidases, which can be used as chemical probes to study the degradation of PG. To address this, diamide masarimycin (previously termed as fgkc) has been identified and characterized³⁵ as a bacteriostatic inhibitor of *Bacillus subtilis* growth that targets the GlcNAcase LytG³² (**Figure 1**). LytG is an *exo*-acting GlcNAcase³⁶, a member of cluster 2 within glycosyl hydrolase family 73 (GH73). It is the major active GlcNAcase during vegetative growth³². To our knowledge, masarimycin is the first inhibitor of a PG-acting GlcNAcase that inhibits cellular growth. Additional studies of masarimycin with *Streptococcus pneumoniae* found that masarimycin likely inhibits cell wall metabolism in this organism³⁷. Here,

the preparation of masarimycin is reported for use as a chemical biology probe to study physiology in the Gram-positive organisms *B. subtilis*, and *S. pneumoniae*. Examples of morphological analysis of sub-minimum inhibitory concentration treatment with masarimycin, as well as a synergy/antagonism assay are presented. Synergy and antagonism assays using antibiotics with well-defined modes of action can be a useful way to explore connections between cellular processes^{38–40}.

PROTOCOL:

1. General methods

NOTE: All compounds were purchased from standard suppliers and used without further purification.

1.1 Carry out thin-layer chromatography (TLC) on an aluminum plate precoated with silica gel XG F254. Detect spots under a UV lamp, by immersion in *p*-anisaldehyde stain, or by exposing to I₂ vapor.

1.2 Record all nuclear magnetic resonance (NMR) spectra on a 400 MHz spectrometer.

NOTE: ¹H- NMR and ¹³C-NMR spectra were referenced to residual solvent peaks. Coupling constants are given in [Hz] and chemical shifts in [ppm].

1.3 Record atmospheric pressure chemical ionization (APCI) mass spectrometry spectra of masarimycin on a compact mass spectrometer equipped with an atmospheric solids analysis probe.

2. General procedure for preparation of masarimycin

NOTE: Perform the below steps in a fume hood.

2.1 Prepare a 0.1 M solution in methanol of each reactant: cyclohexylamine, cyclohexyl carboxaldehyde, *o*-iodobenzoic acid, and cyclohexyl isocyanide³⁵.

CAUTION: Cyclohexylamine, cyclohexyl isocyanide, and cyclohexyl carboxaldehyde are flammable. They can cause skin corrosion and induce oral, dermal, respiratory, or reproductive toxicity. Keep compounds away from open flames, hot surfaces, and ignition sources. Wear appropriate skin and eye protection, work in a well-ventilated area and avoid inhalation of vapors or mist. For storage, keep bottles tightly closed and store them in a cool, dry place. Store cyclohexyl carboxaldehyde in a desiccator under an N₂ atmosphere.

2.2 Mix 5 mL of cyclohexylamine (0.1 M solution in methanol) and 5 mL of cyclohexyl carboxaldehyde (0.1 M in methanol) in a capped round bottom flask and stir the solution using a

magnetic stir bar on a stir/hot plate for 30 min at 40 °C in a sand bath. Monitor temperature using a thermometer placed approximately 1 cm below the sand surface.

2.3 After 30 min, add 5 mL of cyclohexyl isocyanide (0.1 M solution in methanol) to the solution from step 2.2 and stir for an additional 20 min at 50 °C. Lastly, add 5 mL of *o*-iodobenzoic acid (0.1 M solution in methanol) to the reaction mixture and continue stirring at 55 °C for 3–5 h.

2.4 Monitor the progress of the reaction periodically by TLC approximately every hour after the above reaction mixture had been stirred for 3 h.

2.5 Cut a 3 cm x 6 cm strip of aluminum-backed TLC plate. Using a #2 pencil, draw a line approximately 1 cm from the bottom. Using a glass microcapillary, spot approximately 5 µL of the reaction mixture onto the TLC plate and allow it to dry.

2.6 To a 150 mL beaker, add enough mobile phase (90:10 hexane: isopropanol) to cover the bottom of the beaker. Using a pair of tweezers, carefully place the above TLC plate into the beaker ensuring that the TLC plate enters the mobile phase evenly. Cover the top of the beaker with a piece of tinfoil.

NOTE: Ensure that the mobile phase does not cover the line and spotted sample.

2.7 Allow the mobile phase to travel up the TLC plate until it is approximately 1 cm below the top of the plate. Remove the TLC plate and using a pencil, draw a line indicating the distance traveled by the mobile phase. Allow the TLC plate to dry in a fume hood.

2.8 Once dried, place the TLC plate in a beaker containing a small amount of solid I₂ and cover the beaker with a piece of tin foil. Monitor the TLC for the development of yellow/brown spots. Once developed, remove the TLC plate and mark the location of the spots using a pencil (**Supplementary Figure 1**).

NOTE: If I₂ spots are not marked, the stain will dissipate over time. Spots can also be visualized on the TLC plate by UV-light, *p*-anisaldehyde staining, or potassium permanganate staining (see **Supplementary Information**).

2.9 Calculate R_f values for all visualized spots using the following formula:

$$R_f = \frac{\text{distance travelled by spot (mm)}}{\text{distance travelled by mobile phase (mm)}}$$

2.10 Consider the reaction complete when only one spot with R_f = 0.3 is visible on the TLC plate. Remove the solvent in a rotatory evaporator under reduced pressure and dry the crude product (obtained as a yellowish-brown oil) under a high vacuum until all methanol is evaporated.

2.11 Dissolve the dried crude product in 30 mL of ethyl acetate and transfer it to a separatory funnel. Extract ethyl acetate sequentially with 1 M HCl (2 x 30 mL), H₂O (30 mL), saturated

NaHCO₃ solution (2 x 30 mL), H₂O (30 mL) and saturated NaCl solution (2 x 30 mL). Discard the aqueous layers.

NOTE: The ethyl acetate layer is the top layer in each of the extractions. For each extraction, vigorously shake the separatory funnel containing the ethyl acetate and aqueous solution (HCl, H₂O, NaHCO₃, or NaCl) and allow the layers to fully separate.

2.12 Remove the ethyl acetate layer from the separatory funnel and collect it in an Erlenmeyer flask. Add a spatula full of Na₂SO₄ (anhydrous) to remove residual water from ethyl acetate.

NOTE: The ethyl acetate solution is considered dry when Na₂SO₄ in the flask runs freely and does not clump. If Na₂SO₄ is clumping, an additional spatula of Na₂SO₄ can be added.

2.13 Filter the dried ethyl acetate solution through #1 filter paper to remove Na₂SO₄. Wash the filter paper with a small amount of ethyl acetate. Take the filtered ethyl acetate into a round bottom flask and remove the solvent on a rotatory evaporator under reduced pressure to obtain masarimycin as oil once all the ethyl acetate is removed.

2.14 Dissolve the masarimycin oil obtained above in a minimal amount (1–2 mL) of 9:1 hexane: isopropanol and stir on a magnetic stir plate until all the compound is dissolved.

2.15 Purify the dissolved masarimycin by flash chromatography using a 12 g normal phase silica flash column.

2.15.1 Equilibrate the flash column with 10 column volumes of mobile phase (99:1 hexane: isopropanol) with the instrument set at a flow rate of 15 mL/min.

NOTE: After equilibration is completed, stop the flow and disconnect the top of the column from the system.

2.15.2 Draw the dissolved masarimycin using a 5 mL syringe. Connect the syringe directly to the top of the equilibrated flash column and inject the solution into the column. Reconnect the loaded column to the flash chromatography system and initiate the gradient elution.

2.15.3 Elute masarimycin from the column using gradient elution to a final mobile phase concentration of 10:90 hexane: isopropanol over 12 column volumes. Monitor the elution of masarimycin *via* absorption at 230 and 254 nm.

2.15.4 Collect the compounds eluted from the column by a fraction collector that collects 20 mL of solvent per fraction.

NOTE: If a flash chromatography system is not available, purification of masarimycin can be performed *via* a gravity silica column with a 3:1 (hexane: ethyl acetate) mobile phase. Fractions

containing masarimycin can be identified by TLC using the same mobile phase. Visualization of TLC spots was done with either UV light, I₂ vapor, or potassium permanganate staining.

2.15.5 Identify fractions containing masarimycin by TLC (steps 2.5–2.9) or mass spectrometry on a compact mass spectrometer equipped with an atmospheric solids analysis probe. Dry the final product under vacuum (~0.3 mbar).

NOTE: Masarimycin is routinely obtained as a colorless oil or solid with a yield of 55%–70% with respect to mmol of cyclohexyl carboxaldehyde added to the reaction. Calculate the final yield of masarimycin by obtaining the mass of the purified masarimycin and calculating the theoretical yield of the reaction using the following formula:

$$\% \text{ yield} = \frac{\text{mass of purified product}}{\text{theoretical mass of product}} \times 100\%$$

2.16 Confirm the structure of masarimycin by NMR.

2.16.1 Dissolve ~10 mg of masarimycin sample in 0.5 mL of CDCl₃. Using a Pasteur pipet, transfer the solution to a 5 mm NMR tube and cap the tube. Place the NMR tube in the spectrometer.

2.16.2 Acquire ¹H and ¹³C NMR spectra using manufacturer preset experiments. Chemical shift assignments and representative spectra are provided in **Supplementary Figures 3–4**.

2.17 Store masarimycin dry or dissolved in DMSO (25 mM final concentration) at -20 °C until use.

3. Microwave procedure for preparation of masarimycin

3.1 Prepare 0.6 M solutions of cyclohexylamine, cyclohexyl carboxaldehyde, cyclohexyl isocyanide, and o-iodobenzoic acid in acetonitrile.

3.2 Add a stir bar and 10 mL of acetonitrile to a glass microwave reaction vial.

3.3 Add 2 mL of cyclohexylamine (0.6 M in acetonitrile), 2 mL of cyclohexyl carboxaldehyde (0.6 M in acetonitrile), and 7 mL of acetonitrile to the vial.

3.4 Place the microwave reaction vial in the microwave carousel. Stir the mixture, heat it for 30 min at 50 °C at a power setting of 400 W, and allow it to cool to room temperature.

3.5 Add 2 mL of o-iodobenzoic acid (0.6 M in methanol) and 2 mL of cyclohexyl isocyanide (0.6 M in acetonitrile) to the vial. Stir the mixture, heat it to 100 °C in the microwave for 40 min at a power setting of 400 W and allow it to cool to room temperature.

3.6 Monitor the progress of the reaction by TLC (90:10 hexane: isopropanol) using I₂ vapor after the completion of step 3.5.

NOTE: If TLC shows that the reaction is incomplete (i.e., multiple spots on TLC), place the reaction vial back in the microwave and set the microwave conditions described in step 3.5.

3.7 Once the reaction is complete, pour the solution into a 100 mL round-bottom flask and evaporate it to dryness using a rotary evaporator.

3.8 Follow steps 2.6–2.16 above to complete the aqueous workup, purification, and characterization of masarimycin.

4. Synergy and antagonism assay

4.1 Grow *Streptococcus pneumoniae* R6 on Mueller-Hinton (MH) agar plates containing 5% (v/v) sheep blood at 37 °C under anaerobic conditions. In all experiments, use second passage cells grown in 5 mL of MH broth at 37 °C under anaerobic conditions until OD₆₀₀ is ~0.4.

4.2 Subject the inhibitors masarimycin and optochin to serial 1:2 dilutions in respective solvents, with the resulting concentrations flanking the minimum inhibitory concentration (MIC) values of each inhibitor.

4.2.1 Make the initial dilution of masarimycin in dimethyl sulfoxide (DMSO) until a concentration of 100 µM was reached. From this point, make masarimycin dilutions in MH broth. Prepare optochin stock solution (3.5 mM) by dissolving commercially available optochin (see **Table of Materials**) in sterile MH broth.

NOTE: Masarimycin stock solutions were made at 25 mM in DMSO.

4.3 To a sterile 96-well microtitre plate, add 2 µL aliquots of each optochin dilution to each row of the plate. To the same plate, add 2 µL aliquots of each masarimycin dilution to each column to create an array of optochin and masarimycin concentrations on the plate (**Figure 2**).

4.4 Add sterile MH broth (93 µL) to each well containing the above inhibitors. Inoculate the microtitre plates with 5 µL of culture (OD₆₀₀ ~0.4) from step 4.1.

NOTE: Inoculation of the 96-well plate is typically done under anaerobic conditions in an anaerobic workstation. The final volume in the well is 100 µL.

4.5 Grow cultures for 18 h at 37 °C under anaerobic conditions, followed by the addition of 30 µL of 0.01% (m/v) solution of resazurin sodium salt. Incubate the plate at room temperature for 15 min to allow the formation and stabilization of color.

NOTE: Resazurin solution is prepared by dissolving the compound in distilled water and can be stored at 4 °C for up to two weeks.

4.6 Directly read the concentration values from the plate and assign the lowest inhibitor concentration for which no bacterial growth is observed (blue color) as [X] (see step 4.7.1), i.e., the lowest inhibitory concentration of the drug in the presence of the co-drug.

NOTE: Positive bacterial growth is identified in the wells by the resazurin dye turning pink. MIC values for each drug alone (i.e., in the absence of co-drug) are determined in a similar manner using the resazurin MIC assay³⁵ with each drug separately (**Supplemental Figure 5**). MICs in *S. pneumoniae* are 7.8 μ M and 15.85 μ M for masarimycin and optochin, respectively.

4.7 Determine the fractional inhibitory concentration (FIC) and FIC index (FIC_i) using the following equations.

4.7.1 $FIC = [X]/MIC_x$, where [X] (from step 4.6) is the lowest inhibitory concentration of the drug in the presence of the co-drug, and MIC_x is the lowest inhibitory concentration of the drug in the absence of the co-drug.

4.7.2 $FIC_i = FIC_{\text{masarimycin}} + FIC_{\text{antibiotic}}$

NOTE: FIC_i < 0.5 = synergistic, 0.5 < FIC_i < 1 = additive, 1 < FIC_i < 4 = indifferent, FIC_i > 4 = antagonistic.

5. Morphological study

5.1 Grow *Bacillus subtilis* 11774 on Luria-Bertani (LB) agar plates (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl) containing 1.5% Bacto agar at 37 °C. In all experiments, use second passage cells grown in 5 mL of LB broth at 37 °C until OD₆₀₀ = 1. Grow *S. pneumoniae* in the same manner as in step 4.1.

5.2 After obtaining a cell culture density with OD_{600nm} = 1 for *B. subtilis*, or OD_{600nm} = 0.4 for *S. pneumoniae*, add masarimycin using a pipette to the culture tube labeled “treated” to a final concentration of 3.8 μ M (0.75x MIC for *B. subtilis*), or 5.85 μ M (0.75x MIC for *S. pneumoniae*). To the second culture tube labeled “control”, add an equivalent volume of DMSO.

5.3 For *B. subtilis*, place the samples in an incubator at 37 °C for 90 min with shaking at 150 rpm. For *S. pneumoniae*, incubate the cells without shaking under anaerobic conditions.

5.4 After 90 min, chemically fix the cultures in a 1:10 mixture (v/v) of culture media and fixing buffer (20 mM HEPES, 1% formaldehyde (pH 6.8)) at 4 °C overnight. After fixing is complete, apply 10–20 μ L of samples to glass microscope slides using a pipette and allow them to air dry. Fix the air-dried samples by heating the glass slides using a Bunsen burner.

5.5 After heat-fixing, stain samples with the addition of 100 μ L of 0.1% (m/v) methylene blue (solution in 20% (v/v) ethanol). Incubate the stained slides for 10 min and wash away the excess dye with dH₂O. Then, gently heat the stained slides to 60 °C in an oven for 15–20 min to bring

cells to a common focal plane.

5.6 Seal the stained samples by placing a microscope coverslip over the stained cells. Then, seal the edges using microscope slide cement. Place the sealed microscope slide on the microscope stage and bring the image into focus at 100x magnification using bright-field microscopy.

5.7 Place a drop of immersion oil on the microscope slide and bring the field of view to focus using 1000x magnification. Acquire micrographs using a camera attached to the microscope and its associated software. Acquire images using the auto white balance and aperture settings on the software.

NOTE: Alternatively, images can be processed using the open-source ImageJ software.

REPRESENTATIVE RESULTS:

Masarimycin is a small molecule bacteriostatic inhibitor of *B. subtilis* and *S. pneumoniae* and has been shown to inhibit the *exo*-acting GlcNAcase LytG in *B. subtilis*^{35,37} and target the cell wall in *S. pneumoniae*³⁷. Masarimycin can be efficiently prepared either by the classical or microwave-assisted organic synthesis with yields in the 55%–70% range. Microwave-assisted synthesis has the advantage of a significant reduction in time to synthesize the compound. Microwave-assisted synthesis shortens the synthesis from 5–6 h (traditional synthesis) to 2–3 h while maintaining comparable yields. Flash chromatography provides a rapid purification of masarimycin in high purity (**Supplementary Figures 1–2**). Structural assignments from ¹H and ¹³C NMR spectra along with representative spectra are provided in **Supplementary Figures 3–4**.

Synergy and antagonism screens can be a useful tool to reveal functional connections among cellular components (synergy) and to investigate genetic networks and mechanisms of drug action (antagonism)⁴⁰. Evaluation of synergy/antagonism with the ATPase inhibitor optochin in *S. pneumoniae* is presented in **Figure 2**. Resazurin microtitre plate assay⁴¹ provides an easy readout of the growth/non-growth of the organism. The lowest concentration of compound to inhibit bacterial growth (blue color) is taken as the MIC value in the presence of a co-drug. Wells with bacterial growth will be pink in color. The relationship between masarimycin and optochin was determined by calculating the fractional inhibitor concentration index (FIC_i) using equations in protocol step 4.7. The FIC_i value for the masarimycin-optochin interaction is calculated to be 1.5, indicating an indifferent relationship based on published standards⁴². Phenotypic assays using masarimycin in *B. subtilis* at sub-MIC concentrations presented a sausage-like phenotype (**Figure 3B**) which differs from reported phenotypes of the Δ lytG mutant in the literature³² and more closely resembles multiple autolysin knockouts²⁹. Phenotypic analysis of *S. pneumoniae* with masarimycin at sub-MIC concentrations presented a clumping phenotype (**Figure 3D**). This clumping phenotype is distinct from those reported for *S. pneumoniae* cell-wall-acting GlcNAcases^{43–45}.

FIGURE AND TABLE LEGENDS:

Figure 1: Structure of peptidoglycan showing the cleavage site of the *exo*-acting *N*-acetyl glucosaminidase LytG from *Bacillus subtilis*. Inset shows the structure of the LytG inhibitor

masarimycin.

Figure 2: Synergy/Antagonism assay to explore antagonistic/synergistic relationships with masarimycin and optochin in *S. pneumoniae*. Blue or purple color indicates no bacterial growth, while pink color indicates bacterial growth. The MIC in the presence of co-drug is taken as the lowest concentration that shows no bacterial growth (blue color).

Figure 3: Morphological analysis. Morphological changes to *B. subtilis* (A,B) and *S. pneumoniae* (C,D) when treated with 0.75x MIC ($\text{MIC}_{B.\text{subtilis}} = 3.8 \mu\text{M}$ and $\text{MIC}_{S.\text{pneumoniae}} = 7.8 \mu\text{M}$) masarimycin. Cells were fixed and stained with 0.1% (m/v) methylene blue and visualized by bright field microscopy under oil immersion at 1000x magnification. This figure has been modified from ³⁵.

Supplementary Figure 1: Representative thin layer chromatography of masarimycin post aqueous workup. The mobile phase is 90:10 hexane: isopropanol and iodine vapor is used for staining spots. $R_f = 0.3$ for masarimycin.

Supplementary Figure 2: Representative flash chromatogram for the purification of masarimycin. The peak at approximately 1.2 column volumes contains masarimycin.

Supplementary Figure 3: Representative ¹H NMR of masarimycin dissolved in CDCl₃ and recorded on a 400 MHz NMR spectrometer. Spectrum is referenced to residual CHCl₃ solvent peak at $\delta = 7.26$. Numbers in green above chemical shifts indicate proton assignments at the corresponding positions in the structure of masarimycin (see inset).

Supplementary Figure 4: Representative ¹³C NMR spectrum of masarimycin dissolved in CDCl₃ at 100 MHz. Spectrum referenced to residual CHCl₃ solvent peak at $\delta = 77.36$. Numbers in green above chemical shifts indicate carbon atom assignments at the positions in the structure of masarimycin (see inset).

Supplementary Figure 5: Representative resazurin MIC assay of masarimycin against *B. subtilis*.

DISCUSSION:

Masarimycin is a single micromolar bacteriostatic inhibitor of *B. subtilis*³⁵ and *S. pneumoniae*³⁷ growth. In *B. subtilis*, masarimycin has been shown to inhibit the GlcNAcase LytG³⁵, while the precise molecular target in the cell wall of *S. pneumoniae* has not been identified³⁷. Synthesis of masarimycin using either the classical organic synthesis or microwave procedure provides the inhibitor in good yield and high purity. Low yields of masarimycin can typically be attributed to the oxidation of the cyclohexyl carboxaldehyde. To overcome this, it is recommended to store cyclohexyl carboxaldehyde under an inert atmosphere in a desiccator. Oxidation of the aldehyde to the corresponding carboxylic acid can be seen as a white solid in the bottle. Purchasing small quantities of cyclohexyl carboxaldehyde without storing it for extended periods greatly reduces this problem.

NMR assignment of masarimycin structure is complicated by the presence of a mixture of *cis* and

trans forms of the amide bond as well as atropisomers around the *o*-iodophenyl ring that results in multiple peaks. This can result in a proton chemical shift spread over 1 ppm thereby complicating assignments³⁵. As a result, partial assignment of NMR chemical shifts for both ¹H and ¹³C NMR spectra along with representative spectra are provided in **Supplementary Figures 3–4**. If there is difficulty in assigning ¹H and ¹³C chemical shifts for masarimycin due to the mixture of isomers, 2-dimensional NMR experiments can be used. Correlated spectroscopy (COSY) can be used to identify proton spin systems, while heteronuclear single quantum coherence spectroscopy (HSQC) NMR experiments can be used to identify proton-carbon single bond correlations. Once purified, masarimycin can be stored at -20 °C as oil or dissolved in DMSO to a concentration of 25 mM until needed. It is recommended to store in small aliquots to reduce the number of freeze-thaw cycles. After repeated freeze-thaw cycles of the compound, the masarimycin stock solution should be checked by TLC to monitor for any degradation.

Synergy and antagonism screens can be an effective strategy to identify pathway interactions and can be used to understand the mode of action of small molecules. **Figure 2** shows an example of a synergy/antagonism assay with *S. pneumonia* R6 using masarimycin and the ATPase inhibitor optochin (note that the synergy/antagonism screening in *B. subtilis* is still an ongoing investigation). For reproducibility, second passage cells were used and grown to an OD_{600nm} of no more than 0.4. A FIC_i of 1.5 was observed for the interaction between masarimycin and optochin, indicating an indifferent relationship between the antibiotic pair. The indifferent relationship between masarimycin and optochin indicates no apparent interaction between the pathways these antibiotics target. While these assays can provide useful information about drug interactions, it is important to note that synergy/antagonism assays should be run with biological replicates and use of the more conservative cutoffs as described by Odds⁴². This helps to prevent the interpretation of observed minor synergistic or antagonistic relationships.

Phenotypic analysis of *B. subtilis* cells treated with sub-MIC masarimycin (**Figure 3B**) indicates a phenotype that differs from phenotypes reported for genetic deletion of *lytG*³² and more closely resembles phenotypes of *B. subtilis* strains with multiple autolysin deletions²⁹. This discrepancy in phenotype is intriguing because while *in vitro* inhibition of LytG has been demonstrated³⁵, a Δ *lytG* mutant has no observable phenotype³². This discrepancy can in part be explained by differences in genetic and chemical inactivation^{46,47}. The observed differences in the chemical or genetic inactivation of LytG is an intriguing question that is currently under investigation. *S. pneumoniae* cells treated with masarimycin presented a phenotype (**Figure 3D**) distinct from the genetic deletion of the corresponding GlcNAcase (GH73, cluster 2) LytB^{37,43,44,48}. This morphological discrepancy highlights the challenges in assigning the mode of action or attributing the biological target of small molecule inhibitors. Morphological phenotypes can arise from a more complex set of interactions other than a single genetic deletion or chemical inactivation of a cell-wall acting enzyme. These meta-phenotypes³⁴ can arise from complex interactions *via* direct (lack of an enzyme(s)) or indirect (loss of regulators) mechanisms.

To the best of our knowledge, masarimycin is the first inhibitor of a bacterial autolysin that demonstrates inhibition of bacterial growth (**Supplementary Figure 5**). It is a narrow-spectrum bacteriostatic inhibitor of growth in *B. subtilis* and *S. pneumoniae*. This narrow spectrum is a

limitation for multi-species comparative studies of cell-wall metabolism between Gram-positive and Gram-negative organisms. This narrow spectrum is in part due to differences in some of the glycosyl hydrolase autolysins used during vegetative growth between Gram-positive (GlcNAcase) and Gram-negative (lytic transglycosylase) organisms. Using small-molecule inhibitors such as masarimycin for inhibiting PG autolysins, in particular, GlcNAcases can provide an orthogonal approach to traditional genetics for elucidating autolysin function. Masarimycin has a distinct advantage over some chemical biology methods, in that it can be used in more than one species (*B. subtilis* and *S. pneumoniae*). It can allow for comparative studies of cell wall metabolism between rod-shaped (*B. subtilis*) and coccoid (*S. pneumoniae*) species. The less coregulated cell wall metabolism and division in *S. pneumoniae* provides a counter-point in the more tightly regulated system of rod-shaped species^{49,50}. Future applications of this technique will be to identify the molecular target in *S. pneumoniae* and explore the differences between genetic and chemical inactivation of autolysins in *S. pneumoniae* and *B. subtilis*.

Critical Steps in the Protocol

It is important to pay attention to the effective concentration of masarimycin in biological and biochemical assays. Due to its hydrophobic nature, concentrations above 250 μ M (65x MIC in *B. subtilis*) can result in solubility and aggregation issues that can impact the interpretation of biological data. Properly controlling for the effect of vehicle (i.e., DMSO) in all experiments is essential.

ACKNOWLEDGMENTS:

Research was supported by the National Science Foundation under grant number 2009522. NMR analysis of masarimycin was supported by the National Science Foundation major research instrumentation program award under grant number 1919644. Any opinions, findings, and conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

DISCLOSURES:

Reid, C. W. has intellectual property involving specific applications of masarimycin.

REFERENCES:

- 1 Vollmer, W., Blanot, D., de Pedro, M. A. Peptidoglycan structure and architecture. *FEMS Microbiology Review*. **32** (2), 149–167 (2008).
- 2 Munita, J. M., Bayer, A. S., Arias, C. A. Evolving resistance among Gram-positive pathogens. *Clinical Infectious Diseases*. **61** (suppl_2), S48–S57 (2015).
- 3 Vollmer, W., Bertsche, U. Murein (peptidoglycan) structure, architecture and biosynthesis in *Escherichia coli*. *Biochimica Biophysica Acta*. **1778** (9), 1714–1734 (2008).
- 4 Vollmer, W., Hölte, J. -V. The architecture of the murein (peptidoglycan) in Gram-negative bacteria: vertical scaffold or horizontal layer(s)? *Journal of Bacteriology*. **186** (18), 5978–5987 (2004).
- 5 Clarke, A. J. Compositional analysis of peptidoglycan by high-performance anion-exchange chromatography. *Analytical Biochemistry*. **212** (2), 344–350 (1993).
- 6 Kim, S. J., Chang, J., Singh, M. Peptidoglycan architecture of Gram-positive bacteria by

525 solid-state NMR. *Biochimica Biophysica Acta*. **1848** (1 Pt B), 350–362 (2014).

526 7 Koch, A. L., Doyle, R. J. Inside-to-outside growth and turnover of the wall of gram-positive
527 rods. *Journal of Theoretical Biology*. **117** (1), 137–157 (1985).

528 8 Beeby, M., Gumbart, J. C., Roux, B., Jensen, G. J. Architecture and assembly of the Gram-
529 positive cell wall. *Molecular Microbiology*. **88** (4), 664–672 (2013).

530 9 Shockman, G. D., Daneo-Moore, L., Kariyama, R., Massidda, O. Bacterial walls,
531 peptidoglycan hydrolases, autolysins, and autolysis. *Microbial Drug Resistance*. **2** (1), 95–
532 98 (1996).

533 10 Dijkstra, A. J., Keck, W. Peptidoglycan as a barrier to transenvelope transport. *Journal of*
534 *Bacteriology*. **178** (19), 5555–5562 (1996).

535 11 Blackman, S. A., Smith, T. J., Foster, S. J. The role of autolysins during vegetative growth
536 of *Bacillus subtilis* 168. *Microbiology*. **144** (Pt 1) 73–82 (1998).

537 12 Misra, G., Rojas, E. R., Gopinathan, A., Huang, K. C. Mechanical consequences of cell-wall
538 turnover in the elongation of a Gram-positive bacterium. *Biophysical Journal*. **104** (11),
539 2342–2352 (2013).

540 13 Wheeler, R. et al. Bacterial cell enlargement requires control of cell wall stiffness
541 mediated by peptidoglycan hydrolases. *mBio*. **6** (4), e00660, doi:10.1128/mBio.00660-15,
542 (2015).

543 14 Taguchi, A., Kahne, D., Walker, S. Chemical tools to characterize peptidoglycan synthases.
544 *Current Opinion in Chemical Biology*. **53**, 44–50 (2019).

545 15 Welsh, M. A., Schaefer, K., Taguchi, A., Kahne, D., Walker, S. Direction of chain growth and
546 substrate preferences of shape, elongation, division, and sporulation-family
547 peptidoglycan glycosyltransferases. *Journal of the American Chemical Society*. **141** (33),
548 12994–12997 (2019).

549 16 Rubino, F. A. et al. Detection of transport intermediates in the peptidoglycan flippase
550 MurJ identifies residues essential for conformational cycling. *Journal of the American*
551 *Chemical Society*. **142** (12), 5482–5486 (2020).

552 17 Sjodt, M. et al. Structure of the peptidoglycan polymerase RodA resolved by evolutionary
553 coupling analysis. *Nature*. **556** (7699), 118–121 (2018).

554 18 Tiyanont, K. et al. Imaging peptidoglycan biosynthesis in *Bacillus subtilis* with fluorescent
555 antibiotics. *Proceedings of the National Academy of Science U S A*. **103** (29), 11033–11038
556 (2006).

557 19 Lebar, M. D. et al. Reconstitution of peptidoglycan cross-linking leads to improved
558 fluorescent probes of cell wall synthesis. *Journal of the American Chemical Society*. **136**
559 (31), 10874–10877 (2014).

560 20 Do, T., Page, J. E., Walker, S. Uncovering the activities, biological roles, and regulation of
561 bacterial cell wall hydrolases and tailoring enzymes. *Journal of Biological Chemistry*. **295**
562 (10), 3347–3361 (2020).

563 21 Liang, H. et al. Metabolic labelling of the carbohydrate core in bacterial peptidoglycan and
564 its applications. *Nature Communications*. **8**, 15015, (2017).

565 22 DeMeester, K. E. et al. Metabolic incorporation of N-acetyl muramic acid probes into
566 bacterial peptidoglycan. *Current Protocol in Chemical Biology*. **11** (4), e74 (2019).

567 23 Lazor, K. M. et al. Use of Bioorthogonal N-acetylcysteamine (SNAc) analogues and
568 peptidoglycan O-acetyltransferase B (PatB) to label peptidoglycan. *The FASEB Journal*. **32**

(S1), 673.630–673.630 (2018).

24 Wang, Y., Leimkuhler-Grimes, C. Fluorescent labeling of the carbohydrate backbone of peptidoglycan to track degradation in vivo. *The FASEB Journal*. **29** (S1), 718.710 (2015).

25 Kuru, E. et al. In situ probing of newly synthesized peptidoglycan in live bacteria with fluorescent D-amino acids. *Angewandte Chemie International Edition*. **51** (50), 12519–12523 (2012).

26 Zhou, R., Chen, S., Recsei, P. A dye release assay for determination of lysostaphin activity. *Analytical Biochemistry*. **171** (1), 141–144 (1988).

27 Qiao, Y. et al. Lipid II overproduction allows direct assay of transpeptidase inhibition by β -lactams. *Nature Chemical Biology*. **13** (7), 793–798 (2017).

28 Lebar, M. D. et al. Forming cross-linked peptidoglycan from synthetic Gram-negative lipid II. *Journal of the American Chemical Society*. **135** (12), 4632–4635 (2013).

29 Chen, R., Guttenplan, S. B., Blair, K. M., Kearns, D. B. Role of the D-dependent autolysins in *Bacillus subtilis* population heterogeneity. *Journal of Bacteriology*. **191** (18), 5775–5784 (2009).

30 Yukie, S, Miki, K., Yoshio, N., Kuniaki, T., Yoshihisa, Y. Identification and characterization of an autolysin-encoding gene of *Streptococcus mutans*. *Infection and Immunity*. **73** (6), 3512–3520 (2005).

31 Domenech, M., García, E., Moscoso, M. In vitro destruction of *Streptococcus pneumoniae* biofilms with bacterial and phage peptidoglycan hydrolases. *Antimicrobial Agents and Chemotherapy*. **55** (9), 4144–4148 (2011).

32 Horsburgh, G. J., Atrih, A., Williamson, M. P., Foster, S. J. LytG of *Bacillus subtilis* is a novel peptidoglycan hydrolase: the major active glucosaminidase. *Biochemistry*. **42** (2), 257–264 (2003).

33 Vermassen, A. et al. Cell wall hydrolases in bacteria: insight on the diversity of cell wall amidases, glycosidases and peptidases toward peptidoglycan. *Frontiers in Microbiology*. **10**, 331 (2019).

34 Martin-Galiano, A. J., Yuste, J., Cercenado, M. I., de la Campa, A. G. Inspecting the potential physiological and biomedical value of 44 conserved uncharacterised proteins of *Streptococcus pneumoniae*. *BMC Genomics*. **15**, 652 (2014).

35 Nayyab, S. et al. Diamide inhibitors of the *Bacillus subtilis* N-acetylglucosaminidase LytG that exhibit antibacterial activity. *ACS Infectious Diseases*. **3** (6), 421–427 (2017).

36 Lipski, A. et al. Structural and biochemical characterization of the β -N-acetylglucosaminidase from *Thermotoga maritima*: Toward rationalization of mechanistic knowledge in the GH73 family. *Glycobiology*. **25** (3), 319–330 (2014).

37 Haubrich, B. A. et al. Inhibition of *Streptococcus pneumoniae* autolysins highlight distinct differences between chemical and genetic inactivation. *bioRxiv*. 2020.2009.2016.300541 (2020).

38 Farha, M. A. et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β -lactams. *ACS Chemical Biology*. **8** (1), 226–233 (2013).

39 Lehár, J. et al. Chemical combination effects predict connectivity in biological systems. *Molecular Systems Biology*. **3** (1), 80 (2007).

40 Farha, M. A. et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. *Proceedings of the National*

Academy of Science U S A. **112** (35), 11048–11053 (2015).

41 Palomino, J. C. et al. Resazurin microtiter assay plate: simple and inexpensive method for
detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrobial Agents and*
Chemotherapy. **46** (8), 2720–2722 (2002).

42 Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. *Journal*
of Antimicrobial Chemotherapy. **52** (1), 1 (2003).

43 Arrigucci, R., Pozzi, G. Identification of the chain-dispersing peptidoglycan hydrolase LytB
of *Streptococcus gordonii*. *PLoS One.* **12** (4), e0176117 (2017).

44 Bai, X.-H. et al. Structure of pneumococcal peptidoglycan hydrolase LytB reveals insights
into the bacterial cell wall remodeling and pathogenesis *Journal of Biological Chemistry.*
289 (34), 23403–23416 (2014).

45 Garcia, P., Gonzalez, M. P., Garcia, E., Lopez, R., Garcia, J. L. LytB, a novel pneumococcal
murein hydrolase essential for cell separation. *Molecular Microbiology.* **31** (4), 1275–1281
(1999).

46 Giladi, M., Altman-Price, N., Levin, I., Levy, L., Mevarech, M. FolM, a new chromosomally
encoded dihydrofolate reductase in *Escherichia coli*. *Journal of Bacteriology.* **185** (23),
7015–7018 (2003).

47 Chua, P. R. et al. Effective killing of the human pathogen *Candida albicans* by a specific
inhibitor of non-essential mitotic kinesin Kip1p. *Molecular Microbiology.* **65** (2), 347–362
(2007).



48 Rico-Lastres, P. et al. Substrate recognition and catalysis by LytB, a pneumococcal
peptidoglycan hydrolase involved in virulence. *Scientific Reports.* **5**, 16198–16198 (2015).


49 Vollmer, W. et al. The cell wall of *Streptococcus pneumoniae*. *Microbiology Spectrum.* **7**
(3), 7.3.19 (2019).

50 Massidda, O., Nováková, L., Vollmer, W. From models to pathogens: how much have we
learned about *Streptococcus pneumoniae* cell division? *Environmental Microbiology.* **15**
(12), 3133–3157 (2013).


Figure 1

LytG-exo-GlcNAcase







A



B




C



control

D



0.75x MIC masarimycin



Click here to access/download

Table of Materials

JoVE_Materials -final.xlsx





Dec 16, 2021

Re: Revision of manuscript JoVE63191

Dear Dr. Mittal,

We would like to thank the three reviewers and the editorial team for their detailed and highly constructive suggestions for our manuscript. We believe that the changes and suggested revisions have resulted in a much stronger and clearer manuscript for publication in *JoVE*. As indicated in email correspondence, all editorial changes requested have been made using track changes and replies to editorial comments have been added as comments.

We thank you for your careful evaluation and analysis of this manuscript and look forward to your response to these revisions.


Sincerely





Christopher Reid


Professor of Chemistry and Biochemistry














^1H NMR (400 MHz, Chloroform- d_1) δ = 8.45 (m, **NH-20**), 7.85-7.09 (m, 4H, **1,2,3,4**), 3.77 (m, 1H, **22**), 3.33 (d, 1H, **11**), 3.14 (t, 1H, **14**), 2.77 (d, 1H, **13**), 1.91-1.31 (m, 24H, **15,19,23,24,26,27,28,29,30,31,32**), 1.46-0.9 (m, 8H, **16,17,18,25**).

^{13}C NMR (100 MHz, Chloroform- d_1) δ = [172.28, 171.53 – **8,12**], [143.25 – **5**], [139.66, 130.28, 128.35, 125.92 – **1, 2, 3, 4**], [92.84-**6**], [69.05- **11**], [61.66 – **14**], [48.19, **22**], [35.90 – **13**], [33.00, 30.85 – (**23,27**), (**28,32**)], [26.41, 25.88 – (**15,19**), (**16,18**)], [26.07, 26.03, 25.77 – **17, 30, 25**], [25.54, 24.84 – (**24,26**), (**29,31**)] ppm.

Supplementary Information

Preparation of potassium permanganate TLC stain

1. Measure out 1.2 g KMnO_4 , 10.0g K_2CO_3 , and place in a 250 mL beaker.
2. Add 1.25 mL of a 10% NaOH (m/m) solution to the beaker containing KMnO_4 and K_2CO_3
3. Measure out 200 mL of distilled water using a graduated cylinder and add to the beaker. Add a stir bar and place the beaker on a stir plate. Stir the solution until all the solids have dissolved.
4. Store the solution in a capped amber glass bottle for storage.

Preparation of p-anisaldehyde TLC stain

1. Using a graduated cylinder measure out 135 mL of absolute ethanol and add to a 250 mL beaker containing a stir bar
2. Using a graduated cylinder measure out 5 mL of concentrated sulfuric acid and add to the 250 mL beaker from step 1.
3. Using a graduated cylinder measure out 1.5 mL of glacial acetic acid and add to the 250 mL beaker from step 1.
4. Using a graduated cylinder measure out 3.7 mL of p-anisaldehyde and add to the 250 mL beaker from step 1.
5. Place the beaker on a stir plate and stir vigorously until the solution is homogeneous.
6. The stain can be stored in an amber-colored glass jar with a cap until use.

Compact Mass Spectrometer APCI settings

Capillary Temperature: 250°C

Capillary Voltage: 120 V

Source Voltage Offset: 20

Source Voltage Span: 50

Source Gas Temperature: 350°C

APCI Corona Discharge: 5



Home



Help ▾



Email Support



Sign in



Create Account

Diamide Inhibitors of the Bacillus subtilis N-Acetylglucosaminidase LytG That Exhibit Antibacterial Activity



Author: Saman Nayyab, Mary O'Connor, Jennifer Brewster, et al

Publication: ACS Infectious Diseases

Publisher: American Chemical Society

Date: Jun 1, 2017

Copyright © 2017, American Chemical Society

PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE

This type of permission/license, instead of the standard Terms and Conditions, is sent to you because no fee is being charged for your order. Please note the following:

- Permission is granted for your request in both print and electronic formats, and translations.
- If figures and/or tables were requested, they may be adapted or used in part.
- Please print this page for your records and send a copy of it to your publisher/graduate school.
- Appropriate credit for the requested material should be given as follows: "Reprinted (adapted) with permission from {COMPLETE REFERENCE CITATION}. Copyright {YEAR} American Chemical Society." Insert appropriate information in place of the capitalized words.
- One-time permission is granted only for the use specified in your RightsLink request. No additional uses are granted (such as derivative works or other editions). For any uses, please submit a new request.

If credit is given to another source for the material you requested from RightsLink, permission must be obtained from that source.

[BACK](#)

[CLOSE WINDOW](#)



1 Atawite Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

Masarinmycin: a small molecule inhibitor of LysG the
major arabinose bacterial glucosyltransferase in Bacillus
Mika Gallati, Bryant Point, Christopher W. Reed

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Christopher W. Reid

Department:

Science and Technology


Institution:

Bryant University

Title:

Professor

Signature:



Date:

08/09/2021

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140